Clinical Trials Logo

Sintilimab clinical trials

View clinical trials related to Sintilimab.

Filter by:

NCT ID: NCT04180501 Recruiting - Brain Metastases Clinical Trials

SRS Sequential Sindilimab in Brain Metastasis of NSLSC

Start date: November 2019
Phase: Phase 2
Study type: Interventional

A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab

NCT ID: NCT04146831 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

Sintilimab in FH-deficient Renal Cell Carcinoma

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of Sintilimab, a PD-1 Inhibitor, as Second-line Treatment in FH-deficient Renal Cell Carcinoma.

NCT ID: NCT04023916 Not yet recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

Start date: December 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.

NCT ID: NCT03936452 Completed - Radiotherapy Clinical Trials

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Start date: April 28, 2019
Phase: Phase 2
Study type: Interventional

This study aims to investigate the treatment of previously untreated stage I-II Extranodal NK/T Cell Lymphoma with sintilimab, peg-aspargase and anlotinib, "sandwich" with radiotherapy. The primary endpoint is the complete response rate (CRR) at the end of the treatment, and the second endpoints are CRR after two cycles of the combined regimen (CRR2), overall response rate (ORR) at the end of the treatment, survival time (OS and PFS) and toxicities.